Authors Review Impact of Calcium Channel Blockers on Antipsychotic-Induced Tardive Dyskinesia

Authors of a review looked to study the impact of calcium channel blocker therapies (diltiazem, nifedipine, nimodipine, verapamil) in treating patients with neuroleptic-induced tardive dyskinesia (TD) and chronic mental illnesses including schizophrenia and schizoaffective disorder. Researchers used the Cochrane Schizophrenia Group Trials Register (July 2015 and April 2017) to gather information for their research. There were no trials included in prior versions of this review. In their 2015 review, there were three cross-over trials that were included by the researchers, but no new relevant studies in the 2017 review. A total of 47 patients were included in the study from the included trials who had chronic mental illness from both the United States and China. Authors did note that, due to the low availability of evidence, no conclusions could be made on the impact of calcium channel blockers in antipsychotic-induced TD.

Reference: Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;3(3):CD000206. doi:10.1002/14651858.CD000206.pub4

Related Articles